<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37171669</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Current treatment of systemic lupus erythematosus: a clinician's perspective.</ArticleTitle><Pagination><StartPage>1395</StartPage><EndPage>1407</EndPage><MedlinePgn>1395-1407</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-023-05306-5</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Its variable course makes it difficult to standardize patient treatment. This article aims at a literature review on available drugs for treating SLE and on drugs that have shown therapeutic effects in this disease. The PubMed/MEDLINE electronic search engine was used to identify relevant studies. This review presents the current therapeutic options, new biological therapies, and combination therapies of biologics with standard immunosuppressive and immunomodulating drugs. We have also underlined the importance to implement the treat-to-target strategy aimed at reducing or discontinuing therapy with glucocorticosteroids (GCs). The awareness of the benefits and risks of using GCs helps in refining their dosage and thereby obtaining a better safety profile. The advent of biological targeted therapies, and more recently, low-molecular-weight compounds such as kinase inhibitors, initiated numerous clinical trials in SLE patients and led to the approval of two biological drugs, belimumab, and anifrolumab, for SLE treatment. Progress in the treatment of SLE was reflected in the 2019 and 2021 recommendations of the European Alliance of Associations for Rheumatology (EULAR). However, a mass of recent clinical research data requires continuous consolidation to optimize patient outcomes.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katarzyna</LastName><ForeName>Pawlak-Bu&#x15b;</ForeName><Initials>PB</Initials><Identifier Source="ORCID">0000-0002-1982-5980</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Pozna&#x144; University of Medical Sciences, Pozna&#x144;, Poland. k.bus@makabu.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Systemic Connective Tissue Diseases and Immunotherapy of Rheumatic Diseases, J. Stru&#x15b; Municipal Hospital, Pozna&#x144;, Poland. k.bus@makabu.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiktor</LastName><ForeName>Schmidt</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9409-9827</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Systemic Connective Tissue Diseases and Immunotherapy of Rheumatic Diseases, J. Stru&#x15b; Municipal Hospital, Pozna&#x144;, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Doctoral School, Pozna&#x144; University of Medical Sciences, Pozna&#x144;, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewa</LastName><ForeName>Dudziec</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0175-9441</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Pozna&#x144; University of Medical Sciences, Pozna&#x144;, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piotr</LastName><ForeName>Leszczy&#x144;ski</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2174-8811</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Pozna&#x144; University of Medical Sciences, Pozna&#x144;, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Systemic Connective Tissue Diseases and Immunotherapy of Rheumatic Diseases, J. Stru&#x15b; Municipal Hospital, Pozna&#x144;, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001691" MajorTopicYN="N">Biological Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antimalarials</Keyword><Keyword MajorTopicYN="N">Biological therapy</Keyword><Keyword MajorTopicYN="N">Glucocorticoids</Keyword><Keyword MajorTopicYN="N">Immunosuppressants</Keyword><Keyword MajorTopicYN="N">JAK inhibitors</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37171669</ArticleId><ArticleId IdType="pmc">PMC10261264</ArticleId><ArticleId IdType="doi">10.1007/s00296-023-05306-5</ArticleId><ArticleId IdType="pii">10.1007/s00296-023-05306-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014;53:1470&#x2013;1476. doi: 10.1093/rheumatology/keu148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu148</ArticleId><ArticleId IdType="pubmed">24681836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocampo-Piraquive V, Nieto-Aristiz&#xe1;bal I, Ca&#xf1;as CA, et al. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14:1043&#x2013;1053. doi: 10.1080/1744666X.2018.1538789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2018.1538789</ArticleId><ArticleId IdType="pubmed">30338717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016;18:21. doi: 10.1007/s11926-016-0571-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-016-0571-2</ArticleId><ArticleId IdType="pubmed">26984805</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international Taskforce on definitions of remission in SLE (DORIS) Ann Rheum Dis. 2017;76:554&#x2013;561. doi: 10.1136/annrheumdis-2016-209519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209519</ArticleId><ArticleId IdType="pubmed">27884822</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Bertsias G, Doria A, et al. DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8:e000538. doi: 10.1136/lupus-2021-000538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000538</ArticleId><ArticleId IdType="pmc">PMC8614136</ArticleId><ArticleId IdType="pubmed">34819388</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS) Ann Rheum Dis. 2016;75:1615&#x2013;1621. doi: 10.1136/annrheumdis-2015-207726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958&#x2013;967. doi: 10.1136/annrheumdis-2013-205139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205139</ArticleId><ArticleId IdType="pubmed">24739325</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kotopoulou M, Alunno A, et al. update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Tziolos N, Bertsias G, et al. Update &#x3bf;n the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80:14&#x2013;25. doi: 10.1136/annrheumdis-2020-218272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Canny SP, Jackson SW. B Cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies. Rheum Dis Clin North Am. 2021;47:395&#x2013;413. doi: 10.1016/j.rdc.2021.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2021.04.006</ArticleId><ArticleId IdType="pmc">PMC8357318</ArticleId><ArticleId IdType="pubmed">34215370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler HK, Unanue ER. A decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA. 1982;79:175&#x2013;178. doi: 10.1073/pnas.79.1.175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.79.1.175</ArticleId><ArticleId IdType="pmc">PMC345685</ArticleId><ArticleId IdType="pubmed">6798568</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber K, Quraishi H, Kalb TH, et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol. 1993;20:803&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">8336306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA&#x2014;evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006;2:458&#x2013;459. doi: 10.1038/ncprheum0292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncprheum0292</ArticleId><ArticleId IdType="pubmed">16951696</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedoat-Chalumeau N, Galicier L, Auma&#xee;tre O, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study) Ann Rheum Dis. 2013;72:1786&#x2013;1792. doi: 10.1136/annrheumdis-2012-202322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202322</ArticleId><ArticleId IdType="pubmed">23144449</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L, Clarke WA, Magder LS, et al. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42:2092&#x2013;2097. doi: 10.3899/jrheum.150379.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.150379</ArticleId><ArticleId IdType="pmc">PMC4630115</ArticleId><ArticleId IdType="pubmed">26428205</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian Hydroxychloroquine Study Group A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150&#x2013;154. doi: 10.1056/NEJM199101173240303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199101173240303</ArticleId><ArticleId IdType="pubmed">1984192</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsakonas E, Joseph L, Esdaile JM. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7:80&#x2013;85. doi: 10.1191/096120398678919778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120398678919778</ArticleId><ArticleId IdType="pubmed">9541091</ArticleId></ArticleIdList></Reference><Reference><Citation>Sailler L, Puissant B, M&#xe9;liani P, et al. Blood concentrations of hydroxychloroquine and its desmethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients. Ann N Y Acad Sci. 2007;1108:41&#x2013;50. doi: 10.1196/annals.1422.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1422.005</ArticleId><ArticleId IdType="pubmed">17893969</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n GS, Ugarte-Gil MF, Pons-Estel G, et al. Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort. Lupus. 2019;28:423&#x2013;426. doi: 10.1177/0961203319826693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319826693</ArticleId><ArticleId IdType="pubmed">30678605</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakchotanon R, Gladman DD, Su J, et al. Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease, and end-stage renal disease in lupus nephritis. Lupus. 2018;27:468&#x2013;474. doi: 10.1177/0961203317726376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317726376</ArticleId><ArticleId IdType="pubmed">28857717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. M effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577&#x2013;583. doi: 10.1177/0961203306071872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306071872</ArticleId><ArticleId IdType="pubmed">17080912</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) Ann Rheum Dis. 2007;66:1168&#x2013;1172. doi: 10.1136/ard.2006.068676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.068676</ArticleId><ArticleId IdType="pmc">PMC1955128</ArticleId><ArticleId IdType="pubmed">17389655</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinjo SK, Bonf&#xe1; E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62:855&#x2013;862. doi: 10.1002/art.27300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27300</ArticleId><ArticleId IdType="pubmed">20131238</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Alarc&#xf3;n GS, McGwin G, Jr, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Lumina Study Group. Arthritis Rheum. 2009;61:830&#x2013;839. doi: 10.1002/art.24538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24538</ArticleId><ArticleId IdType="pmc">PMC2898742</ArticleId><ArticleId IdType="pubmed">19479701</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman CH, Hiraki LT, Winkelmayer WC, et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 2015;67:1577&#x2013;1585. doi: 10.1002/art.39070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39070</ArticleId><ArticleId IdType="pmc">PMC4446132</ArticleId><ArticleId IdType="pubmed">25772621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11:R109. doi: 10.1186/ar2764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2764</ArticleId><ArticleId IdType="pmc">PMC2745791</ArticleId><ArticleId IdType="pubmed">19604357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:775&#x2013;784. doi: 10.1002/acr.20133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20133</ArticleId><ArticleId IdType="pubmed">20535788</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai T, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision) Ophthalmology. 2016;123:1386&#x2013;1394. doi: 10.1016/j.ophtha.2016.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.01.058</ArticleId><ArticleId IdType="pubmed">26992838</ArticleId></ArticleIdList></Reference><Reference><Citation>Amissah-Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis. 2010;1:163&#x2013;175. doi: 10.1177/2040622310380100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040622310380100</ArticleId><ArticleId IdType="pmc">PMC3513867</ArticleId><ArticleId IdType="pubmed">23251736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhengyan H, Rui G, Wanrong H, et al. Effect of hydroxychloroquine on lupus activity, preeclampsia and intrauterine growth restriction in pregnant women with systemic lupus erythematosus and/or antiphospholipid syndrome: a systematic review and meta-analysis. J Clin Med. 2023;12:485. doi: 10.3390/jcm12020485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12020485</ArticleId><ArticleId IdType="pmc">PMC9866542</ArticleId><ArticleId IdType="pubmed">36675415</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves P, Bashir MM, Wysocka M, et al. Quinacrine suppresses tumor necrosis factor-&#x3b1; and IFN-&#x3b1; in dermatomyositis and cutaneous lupus erythematosus. J Investig Dermatol Symp Proc. 2017;18:S57&#x2013;63. doi: 10.1016/j.jisp.2016.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jisp.2016.11.001</ArticleId><ArticleId IdType="pmc">PMC5645024</ArticleId><ArticleId IdType="pubmed">28941496</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ. The use of quinacrine (atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum. 1989;18:282&#x2013;296. doi: 10.1016/0049-0172(89)90050-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-0172(89)90050-4</ArticleId><ArticleId IdType="pubmed">2658071</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia WY, Zhang JJ. Effects of glucocorticoids on leukocytes: genomic and non-genomic mechanisms. World J Clin Cases. 2022;10:7187&#x2013;7194. doi: 10.12998/wjcc.v10.i21.7187.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v10.i21.7187</ArticleId><ArticleId IdType="pmc">PMC9353929</ArticleId><ArticleId IdType="pubmed">36158016</ArticleId></ArticleIdList></Reference><Reference><Citation>Little J, Parker B, Lunt M, et al. Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort. Rheumatology (Oxford) 2018;57:677&#x2013;687. doi: 10.1093/rheumatology/kex444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex444</ArticleId><ArticleId IdType="pmc">PMC5888922</ArticleId><ArticleId IdType="pubmed">29361147</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pubmed">12966597</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, et al. Independent association of glucocorticoids with damage accrual in SLE. Lupus Sci Med. 2016;3:e000157. doi: 10.1136/lupus-2016-000157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000157</ArticleId><ArticleId IdType="pmc">PMC5133410</ArticleId><ArticleId IdType="pubmed">27933196</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers SA, Allen E, Rahman A, et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology. 2009;48:673&#x2013;675. doi: 10.1093/rheumatology/kep062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep062</ArticleId><ArticleId IdType="pubmed">19359343</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4:525&#x2013;533. doi: 10.1038/ncprheum0898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncprheum0898</ArticleId><ArticleId IdType="pubmed">18762788</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, Danza A, Arias Saavedra M, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9:2709. doi: 10.3390/jcm9092709.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9092709</ArticleId><ArticleId IdType="pmc">PMC7563630</ArticleId><ArticleId IdType="pubmed">32839376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology. 2012;51:1145&#x2013;1153. doi: 10.1093/rheumatology/ker410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker410</ArticleId><ArticleId IdType="pubmed">22271756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lightstone L, Doria A, Wilson H, et al. Can we manage lupus nephritis without chronic corticosteroid administration? Autoimmun Rev. 2018;17:4&#x2013;10. doi: 10.1016/j.autrev.2017.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.11.002</ArticleId><ArticleId IdType="pubmed">29108828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res. 2018;70:582&#x2013;591. doi: 10.1002/acr.23322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23322</ArticleId><ArticleId IdType="pubmed">28704598</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolopoulos D, Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford) 2017;56:i114&#x2013;i122. doi: 10.1093/rheumatology/kew406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew406</ArticleId><ArticleId IdType="pubmed">28013208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Ramos-Casals M, Brito-Zer&#xf3;n P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20&#x2013;28. doi: 10.1136/ard.2008.101766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.101766</ArticleId><ArticleId IdType="pubmed">19103632</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59:1796&#x2013;1804. doi: 10.1002/art.24068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24068</ArticleId><ArticleId IdType="pubmed">19035431</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League against rheumatism and European renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and pediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771&#x2013;1782. doi: 10.1136/annrheumdis-2012-201940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201940</ArticleId><ArticleId IdType="pmc">PMC3465859</ArticleId><ArticleId IdType="pubmed">22851469</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji L, Xie W, Zhang Z. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology (Oxford) 2021;60:5517&#x2013;5526. doi: 10.1093/rheumatology/keab149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab149</ArticleId><ArticleId IdType="pubmed">33576768</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Gladman DD, Su J, et al. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol. 2021;3:550&#x2013;557. doi: 10.1002/acr2.11267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11267</ArticleId><ArticleId IdType="pmc">PMC8363847</ArticleId><ArticleId IdType="pubmed">34245233</ArticleId></ArticleIdList></Reference><Reference><Citation>Fardet L, Petersen I, Nazareth I. Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med. 2016;13:e1002024. doi: 10.1371/journal.pmed.1002024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002024</ArticleId><ArticleId IdType="pmc">PMC4878789</ArticleId><ArticleId IdType="pubmed">27218256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DY, Lee P, Tam C, et al. B cell subsets and signatures in lupus nephritis patients receiving mycophenolate or azathioprine maintenance. J Am Soc Nephrol. 2018;29:336. doi: 10.3389/fimmu.2020.01732.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01732</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, Vasconcelos C, D&#x2019;Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121&#x2013;2131. doi: 10.1002/art.10461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10461</ArticleId><ArticleId IdType="pubmed">12209517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;6:CD002922. doi: 10.1002/14651858.CD002922.pub4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002922.pub4</ArticleId><ArticleId IdType="pmc">PMC6513226</ArticleId><ArticleId IdType="pubmed">29957821</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Solomons N, Pendergraft WF, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95:219&#x2013;231. doi: 10.1016/j.kint.2018.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.08.025</ArticleId><ArticleId IdType="pubmed">30420324</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio J, Kyttaris V. Journal Club: Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomized, multicenter, placebo-controlled, phase 3 trial. ACR Open Rheumatol. 2021;3:827&#x2013;831. doi: 10.1002/acr2.11338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11338</ArticleId><ArticleId IdType="pmc">PMC8672170</ArticleId><ArticleId IdType="pubmed">34463434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok C, Ho L, Yin S, et al. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis. 2020;79:1070&#x2013;1076. doi: 10.1136/annrheumdis-2020-217178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217178</ArticleId><ArticleId IdType="pubmed">32448782</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollinghoff M, Schrader J, Wagner H. Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro. Clin Exp Immunol. 1973;15:261&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1553882</ArticleId><ArticleId IdType="pubmed">4543428</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorski A, Korczak-Kowalska G, Nowaczyk M, et al. The effect of azathioprine on terminal differentiation of human B lymphocytes. Immunopharmacology. 1983;6:259&#x2013;266. doi: 10.1016/0162-3109(83)90032-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0162-3109(83)90032-2</ArticleId><ArticleId IdType="pubmed">6228535</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannon CW, McCourt C, Lima HC, et al. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;3:CD007478. doi: 10.1002/14651858.CD007478.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD007478.pub2</ArticleId><ArticleId IdType="pmc">PMC8092459</ArticleId><ArticleId IdType="pubmed">33687069</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119:1066&#x2013;1673. doi: 10.1172/JCI38010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI38010</ArticleId><ArticleId IdType="pmc">PMC2673851</ArticleId><ArticleId IdType="pubmed">19411764</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra S, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:721&#x2013;731. doi: 10.1016/S0140-6736(10)61354-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, et al. A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918&#x2013;3930. doi: 10.1002/art.30613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Rovin BH, Joussai F, et al. Two-year, randomized controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117&#x2013;1128. doi: 10.1056/NEJMoa2001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Yazdany J, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev. 2017;16:287&#x2013;293. doi: 10.1016/j.autrev.2017.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.01.010</ArticleId><ArticleId IdType="pubmed">28147262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550&#x2013;2557. doi: 10.1002/art.21955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21955</ArticleId><ArticleId IdType="pubmed">16868977</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicenter, randomized, double blind, placebo-controlled study. Ann Rheum Dis. 2016;75:323&#x2013;331. doi: 10.1136/annrheumdis-2015-207653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207653</ArticleId><ArticleId IdType="pubmed">26338095</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, van Vollenhoven RF, Buyon JF, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:332&#x2013;340. doi: 10.1136/annrheumdis-2015-207654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207654</ArticleId><ArticleId IdType="pubmed">26293163</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-tosevere systemic lupus erythematosus: 52-week data (APRIL-SLE randomized trial) Ann Rheum Dis. 2015;74:2006&#x2013;2015. doi: 10.1136/annrheumdis-2013-205067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205067</ArticleId><ArticleId IdType="pmc">PMC4680140</ArticleId><ArticleId IdType="pubmed">24951103</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70:266&#x2013;276. doi: 10.1002/art.40360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40360</ArticleId><ArticleId IdType="pmc">PMC6099253</ArticleId><ArticleId IdType="pubmed">29073347</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E, Isenberg DA, Wallace DJ, et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase IIb ADDRESS II study. Rheumatology. 2020;59:2930&#x2013;2938. doi: 10.1093/rheumatology/keaa029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa029</ArticleId><ArticleId IdType="pmc">PMC7516108</ArticleId><ArticleId IdType="pubmed">32107560</ArticleId></ArticleIdList></Reference><Reference><Citation>Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2:676&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3512181</ArticleId><ArticleId IdType="pubmed">23226614</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial (EXPLORER) Arthritis Rheum. 2010;62:222&#x2013;233. doi: 10.1002/art.27233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27233</ArticleId><ArticleId IdType="pmc">PMC4548300</ArticleId><ArticleId IdType="pubmed">20039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215&#x2013;1226. doi: 10.1002/art.34359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34359</ArticleId><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13:1502&#x2013;1509. doi: 10.2215/CJN.01070118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01070118</ArticleId><ArticleId IdType="pmc">PMC6218830</ArticleId><ArticleId IdType="pubmed">30089664</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis. 2008;67:1724&#x2013;1731. doi: 10.1136/ard.2007.083162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.083162</ArticleId><ArticleId IdType="pubmed">18250115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767&#x2013;776. doi: 10.1177/0961203309106174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309106174</ArticleId><ArticleId IdType="pubmed">19578100</ArticleId></ArticleIdList></Reference><Reference><Citation>Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364&#x2013;372. doi: 10.1016/j.semarthrit.2011.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2011.06.004</ArticleId><ArticleId IdType="pubmed">21875742</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470&#x2013;475. doi: 10.1136/ard.2006.057885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.057885</ArticleId><ArticleId IdType="pmc">PMC1856059</ArticleId><ArticleId IdType="pubmed">17107983</ArticleId></ArticleIdList></Reference><Reference><Citation>Bag-Ozbek A, Hui-Yuen JS. Emerging B cell therapies in systemic lupus erythematosus. Ther Clin Risk Manag. 2021;17:39&#x2013;54. doi: 10.2147/TCRM.S252592.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S252592</ArticleId><ArticleId IdType="pmc">PMC7814238</ArticleId><ArticleId IdType="pubmed">33488082</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, June J, Koumpouras F, et al. Top-line results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb&#xae;5871, in systemic lupus erythematosus (SLE) Lupus Sci Med. 2018 doi: 10.1136/lupus-2019-lsm.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-lsm.98</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Clowse MEB, Wallace DJ, Furie RA, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017;69:362&#x2013;375. doi: 10.1002/art.39856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39856</ArticleId><ArticleId IdType="pmc">PMC5299488</ArticleId><ArticleId IdType="pubmed">27598855</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicenter studies (ALLEVIATE) and follow-up. Rheumatology. 2013;52:1313&#x2013;1322. doi: 10.1093/rheumatology/ket129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket129</ArticleId><ArticleId IdType="pubmed">23542611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyuan IT, Tzeng HT, Chen JY. Signaling pathways of type I and type III Interferons and targeted therapies in systemic lupus erythematosus. Cells. 2019;8:963. doi: 10.3390/cells8090963.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8090963</ArticleId><ArticleId IdType="pmc">PMC6769759</ArticleId><ArticleId IdType="pubmed">31450787</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376&#x2013;386. doi: 10.1002/art.39962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis MM, Way SS, Wilson CB. IL-23 promotes the production of IL-17 by antigen-specific CD8 T cells in the absence of IL-12 and type-I interferons. J Immunol. 2009;183:381&#x2013;387. doi: 10.4049/jimmunol.0900939.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900939</ArticleId><ArticleId IdType="pmc">PMC2729917</ArticleId><ArticleId IdType="pubmed">19542449</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton CE, Lalor SJ, Sweeney CM, et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31:331&#x2013;341. doi: 10.1016/j.immuni.2009.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.08.001</ArticleId><ArticleId IdType="pubmed">19682929</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R, Hahn BH, Rose S, et al. Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomized placebo-controlled study. Lancet. 2018;392:1330&#x2013;1339. doi: 10.3899/jrheum.210805.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.210805</ArticleId><ArticleId IdType="pubmed">30249507</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaglioni V, Scolnik M, Soriano ER et al (2018) Refractory Lupus Patients: How Frequent Do We See Them in the 21st Century? [Abstract]. Arthritis Rheumatol 70(suppl 9). https://acrabstracts.org/abstract/refractory-lupus-patients-how-frequent-do-we-see-them-in-the-21st-century/</Citation></Reference><Reference><Citation>Atisha F, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2020;73:121&#x2013;131. doi: 10.1002/art.41466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41466</ArticleId><ArticleId IdType="pmc">PMC7839443</ArticleId><ArticleId IdType="pubmed">32755035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipa M, Embleton-Thirsk A, Parvaz M, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial. Ann Intern Med. 2021;174:1647&#x2013;1657. doi: 10.7326/M21-2078.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-2078</ArticleId><ArticleId IdType="pubmed">34698499</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xf6;wall C, Hjorth M, Eriksson P. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus. 2017;26:1333&#x2013;1338. doi: 10.1177/0961203317691371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317691371</ArticleId><ArticleId IdType="pubmed">28162031</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadina M, Le MT, Schwartz DM, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford) 2019;58(Suppl 1):i4&#x2013;i16. doi: 10.1093/rheumatology/key432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key432</ArticleId><ArticleId IdType="pmc">PMC6657570</ArticleId><ArticleId IdType="pubmed">30806710</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:222&#x2013;231. doi: 10.1016/S0140-6736(18)31363-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31363-1</ArticleId><ArticleId IdType="pubmed">30043749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonciarz M, Pawlak-Bu&#x15b; K, Leszczy&#x144;ski P, et al. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy. 2021;13:1135&#x2013;1150. doi: 10.2217/imt-2021-0096.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2021-0096</ArticleId><ArticleId IdType="pubmed">34235974</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E, Pike JT, Merrill R. Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo controlled study. Ann Rheum Dis. 2022;81:209. doi: 10.1136/annrheumdis-2022-eular.5020a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.5020a</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Furie RA, Jones N, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2021;73:1835&#x2013;1846. doi: 10.1002/art.41811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41811</ArticleId><ArticleId IdType="pubmed">34042314</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74:1474&#x2013;1478. doi: 10.1136/annrheumdis-2014-206016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206016</ArticleId><ArticleId IdType="pmc">PMC4484251</ArticleId><ArticleId IdType="pubmed">25710470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Tanaka Y, Kawakami A, et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018;28:986&#x2013;992. doi: 10.1080/14397595.2018.1432331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1432331</ArticleId><ArticleId IdType="pubmed">29363990</ArticleId></ArticleIdList></Reference><Reference><Citation>Lever E, Alves MR, Isenberg DA. Towards precision medicine in systemic lupus erythematosus. Pharmgenomics Pers Med. 2020;13:39&#x2013;49. doi: 10.2147/PGPM.S205079.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PGPM.S205079</ArticleId><ArticleId IdType="pmc">PMC7007776</ArticleId><ArticleId IdType="pubmed">32099443</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>